Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PTH recombinant mesenchymal stem cells
- Development stage
- Unknown
- Lead developer
- Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine
- Modality
- Gene Therapies, Stem Cell Therapies → Cell Therapies
- Administration
- Intramuscular, Intravenous
01
Overview
PTH recombinant mesenchymal stem cells (PTH-rhMSC) is an investigational cell-based gene therapy consisting of mesenchymal stem cells (MSCs) that have been genetically engineered to express and secrete recombinant parathyroid hormone (PTH). Developed by the Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine, this therapy is designed to treat hypoparathyroidism, including idiopathic and postsurgical forms. By providing a continuous, endogenous-like source of PTH, the therapy aims to restore physiological calcium and phosphate homeostasis, potentially reducing or eliminating the need for chronic oral calcium and calcitriol supplementation. The product is currently being evaluated in Phase 1/2 clinical trials to assess its safety, tolerability, and preliminary efficacy in adult patients.
- Other names
- PTH-modified mesenchymal stem cellsPTH-expressing MSCsparathyroid hormone recombinant mesenchymal stem cells
02
Targets
PTH1R (Parathyroid hormone/Parathyroid hormone-related peptide receptor type 1)
Beyond the preview
Go deeper on PTH recombinant mesenchymal stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PTH recombinant mesenchymal stem cells.